Osteoarthritis is a chronic disease that affects the joints, causing pain, stiffness, and swelling. It is the most common type of arthritis and affects millions of people worldwide. While there is no cure for osteoarthritis, there are treatments that can help reduce its symptoms and slow its progression.
The main treatment for osteoarthritis is medications. Nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen or naproxen, are commonly prescribed. These drugs can reduce pain and inflammation. Other medications, such as glucosamine and chondroitin, may help slow the progression of the disease. In addition to medications, physical therapy and lifestyle changes are important components of osteoarthritis treatment. Physical therapy can help strengthen the muscles around the affected joints, reduce pain, and improve mobility. Exercise, such as swimming, walking, and cycling, can also be beneficial.
Currently, "Osteoarthritis Therapeutics Market by Anatomy (Knee, Hand), Drug Type (NSAIDs, Analgesics, Corticosteroids), Route of Administration (Parenteral), Distribution Channel (Hospital Pharmacies),Purchasing Pattern (Prescription Drugs)-Global Forecast to 2025", The Global Osteoarthritis Therapeutics Market is projected to reach USD 11.0 billion by 2025 from USD 7.3 billion in 2020, at a CAGR of 8.7% from 2020 to 2025. The growth of this market is driven by significant adoption of pain medications, increasing prevalence of osteoarthritis, growing population susceptible to osteoarthritis, and rising number of sports injuries.
The presence of a large geriatric and target patient population and the improving healthcare infrastructure in several APAC countries are expected to offer growth opportunities in the market during the forecast period.
Request for assumptions how numbers were triangulated.
https://www.marketsandmarkets.com/requestsampleNew.asp?id=209565994
Market Growth Drivers
- Rising government investments in cell-based research significant adoption of pain medications
Market Growth Opportunities
- Personalized medicine for osteoarthritis
Market RESTRAINTS
- Risk of adverse cardiovascular events associated with the use of NSAIDs in osteoarthritis treatment
Industry Trends
- Remarkable advances have been made in diagnosing, treating, and monitoring disease activity in patients with osteoarthritis, including the conceptualization of personalized OA medications. Essential features of biomarkers that will have clinical relevance for a personalized approach to therapy for RA include the ease of measurement
Download an Illustrative Overview:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=209565994
The major players operating in this market are Sanofi (France), Horizon Therapeutics PLC (Ireland), Johnson Johnson (US), GlaxoSmithKline PLC (UK), Bayer AG (Germany), Abbott (US), Pfizer, Inc. (US), Eli Lilly (US), Anika Therapeutics, Inc. (US), Novartis AG (Switzerland), Ferring Pharmaceuticals (Switzerland), Bioventus (US), Zimmer Biomet Holdings, Inc. (US), Fidia Farmaceutici s.p.a. (Italy), Flexion Therapeutics, Inc. (US), Pharmed Limited (India), Virchow Biotech (India), Kitov Pharmaceuticals Ltd. (Israel), Assertio Therapeutics, Inc. (US), Atnahs (UK), Almatica Pharma LLC (US), OrthogenRx (US), LABRHA (France), Hanmi Pharm. Co., Ltd. (Korea), and Laboratorio Reig Jofre (Spain).
Research Developments
- In 2020, GlaxoSmithKline Plc (UK) launched Voltaren in the US.
- In 2020, Horizon Therapeutics Plc (Ireland) expanded its presence in the US.
- In 2019, Kitov Pharma Ltd. (Israel) entered into an agreement with Coeptis Pharmaceuticals which has helped in the efficient distribution and commercialization of Consensi.
- In 2018, Atnahs established a sales office in Dubai, UAE.
- In 2017, Flexion Therapeutics, Inc. (US) received FDA Approval for ZILRETTA
Content Source:
